Drug intelligence / Profile preview

omega-3 + aspirin

Development stage
Unknown
Lead developer
GSK
Modality
Small Molecules
Administration
Oral
01

Overview

A combination of omega-3 fatty acids (primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) and aspirin (acetylsalicylic acid). This combination has been studied for its effects on cardiovascular disease prevention and other conditions. Omega-3 fatty acids are polyunsaturated fatty acids that have anti-inflammatory properties. Aspirin is a well-established antiplatelet agent that works by permanently inactivating cyclooxygenase enzymes. Research indicates a complex interaction between aspirin use and omega-3 fatty acid levels in the body. The relationship between omega-3 levels and cardiovascular disease risk may vary depending on whether a person is taking aspirin, potentially showing a "U-shaped" interactive effect where aspirin's efficacy may depend on the concentration of omega-3 fatty acids in the blood. Regarding safety, one study suggests that the combination of low-dose aspirin and omega-3 fatty acids does not significantly increase the risk of upper gastrointestinal complications compared to aspirin alone.

Other names
aspirin + DHA + EPAaspirin plus omega-3 fatty acidsaspirin plus fish oil
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PTGER4 (Prostaglandin E2 receptor EP4 subtype)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on omega-3 + aspirin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on omega-3 + aspirin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call